Early Combined Immunosuppression in Crohn's Disease: Acting Rather Than REACTing

Affiliations

¹ Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandoeuvre, France.
² IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.

Comment

Laurent Peyrin-Biroulet et al. Gastroenterology. 2016 Apr.

. 2016 Apr;150(4):1040-1.

doi: 10.1053/j.gastro.2016.02.056. Epub 2016 Feb 27.

¹ Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Université de Lorraine, Vandoeuvre, France.
² IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.

No abstract available

Comment in

Reply.
Khanna R, Feagan BG; REACT Investigators. Khanna R, et al. Gastroenterology. 2016 Apr;150(4):1041-2. doi: 10.1053/j.gastro.2016.02.057. Epub 2016 Feb 27. Gastroenterology. 2016. PMID: 26926451 No abstract available.

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators. Khanna R, et al. Lancet. 2015 Nov 7;386(10006):1825-34. doi: 10.1016/S0140-6736(15)00068-9. Epub 2015 Sep 3. Lancet. 2015. PMID: 26342731 Clinical Trial.